Linearizable 3-webs and the Gronwall conjecture

In the article "On the linearizability of 3-webs" (Nonlinear analysis 47, (2001) pp.2643-2654), published in 2001, we studied the linearizability problem for 3-webs on a 2-dimensional manifold. Four years after the publication of our article, V.V.Goldberg and V.V.Lychagin in the paper "On linearization of planar three-webs and Blaschke's conjecture" (C.R.Acad. Sci. Paris, Ser. I. vol. 341. num 3 (2005)) obtained similar results by a different method and criticized our article by qualifying the proofs incomplete. However, they obtained false result on the linearizability of a certain web. We present here the complete version of our work with computations and explicit formulas, because we deem that their opinion concerning our work is unjustified.Comment: 14 page

Parallel-Concurrent Versus Concurrent Fault Simulation

Coordinated Science Laboratory was formerly known as Control Systems LaboratorySemiconductor Research Corporation (SRC) / 86-12-10

International support for the Arab uprisings: Understanding sympathetic collective action using theories of social dominance and social identity

Inspired by the popular Arab protests against oppressive regimes that began in 2010, people around the world protested in sympathy with the Arab peoples. The present research draws on two major theories of intergroup relations to develop an initial integrative model of sympathetic collective action. We incorporate social dominance theory’s (SDT) concept of (rejectionist) legitimizing myths with the solidarity and emotional mediation concept of the social identity model of collective action (SIMCA) to understand motivations for sympathetic collective action among bystanders. Using data from 12 nations (N = 1,480), we tested three models: (a) SIMCA (i.e., solidarity, anger, and efficacy), (b) a social dominance theory model of collective action (i.e., social dominance orientation and ideologies concerning Arab competence), and (c) an integrated model of sympathetic collective action combining both theories. Results find the greatest support for an integrated model of collective action. Discussion focuses on theoretical pluralism and suggestions for future research

Physicochemical Properties of Chemical Pollutants Available in Food Contact Materials (FCM)

Health and welfare of population are priority reasons to study the toxic effects of chemical pollutants. These effects can directly produce deterioration of health or can cause less healthful environment toxicity and restricting food production. Thereby, preventing such a consequence is important for human health risk assessment. In recent times, the use of recycled materials for packaging has undeniably been intensified. Nevertheless, recycling systems could not effectively eliminate the potential effect of chemical pollutants (alkyl phenol, phthalates, aldehydes, etc.) existent in such packages. The migration process and/or the ability of these pollutants to be absorbed into the recycled material, subsequently released by the packaging material, and then trapped by the matrices they contain, has become a potential source of exposure to consumers. This process is controlled by the nature of the packaging, time, temperature, and the physicochemical properties of the contaminant. The literature suffers from a lack of data related to the physicochemical (aqueous solubility, vapor pressure, Henry’s constant, etc...) of these contaminants. In this work, we are going to describe the experimental devices used for aqueous solubility, vapor pressure and octanol/water partition coefficient determination

A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/99090/1/cncr28117.pd

US Cosmic Visions: New Ideas in Dark Matter 2017: Community Report

This white paper summarizes the workshop "U.S. Cosmic Visions: New Ideas in Dark Matter" held at University of Maryland on March 23-25, 2017.Comment: 102 pages + reference

Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation

BACKGROUND: Liver biopsy is the reference standard for diagnosing the extent of fibrosis in chronic liver disease; however, it is invasive, with the potential for serious complications. Alternatives to biopsy include non-invasive liver tests (NILTs); however, the cost-effectiveness of these needs to be established. OBJECTIVE: To assess the diagnostic accuracy and cost-effectiveness of NILTs in patients with chronic liver disease. DATA SOURCES: We searched various databases from 1998 to April 2012, recent conference proceedings and reference lists. METHODS: We included studies that assessed the diagnostic accuracy of NILTs using liver biopsy as the reference standard. Diagnostic studies were assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Meta-analysis was conducted using the bivariate random-effects model with correlation between sensitivity and specificity (whenever possible). Decision models were used to evaluate the cost-effectiveness of the NILTs. Expected costs were estimated using a NHS perspective and health outcomes were measured as quality-adjusted life-years (QALYs). Markov models were developed to estimate long-term costs and QALYs following testing, and antiviral treatment where indicated, for chronic hepatitis B (HBV) and chronic hepatitis C (HCV). NILTs were compared with each other, sequential testing strategies, biopsy and strategies including no testing. For alcoholic liver disease (ALD), we assessed the cost-effectiveness of NILTs in the context of potentially increasing abstinence from alcohol. Owing to a lack of data and treatments specifically for fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), the analysis was limited to an incremental cost per correct diagnosis. An analysis of NILTs to identify patients with cirrhosis for increased monitoring was also conducted. RESULTS: Given a cost-effectiveness threshold of £20,000 per QALY, treating everyone with HCV without prior testing was cost-effective with an incremental cost-effectiveness ratio (ICER) of £9204. This was robust in most sensitivity analyses but sensitive to the extent of treatment benefit for patients with mild fibrosis. For HBV [hepatitis B e antigen (HBeAg)-negative)] this strategy had an ICER of £28,137, which was cost-effective only if the upper bound of the standard UK cost-effectiveness threshold range (£30,000) is acceptable. For HBeAg-positive disease, two NILTs applied sequentially (hyaluronic acid and magnetic resonance elastography) were cost-effective at a £20,000 threshold (ICER: £19,612); however, the results were highly uncertain, with several test strategies having similar expected outcomes and costs. For patients with ALD, liver biopsy was the cost-effective strategy, with an ICER of £822. LIMITATIONS: A substantial number of tests had only one study from which diagnostic accuracy was derived; therefore, there is a high risk of bias. Most NILTs did not have validated cut-offs for diagnosis of specific fibrosis stages. The findings of the ALD model were dependent on assuptions about abstinence rates assumptions and the modelling approach for NAFLD was hindered by the lack of evidence on clinically effective treatments. CONCLUSIONS: Treating everyone without NILTs is cost-effective for patients with HCV, but only for HBeAg-negative if the higher cost-effectiveness threshold is appropriate. For HBeAg-positive, two NILTs applied sequentially were cost-effective but highly uncertain. Further evidence for treatment effectiveness is required for ALD and NAFLD. STUDY REGISTRATION: This study is registered as PROSPERO CRD42011001561. FUNDING: The National Institute for Health Research Health Technology Assessment programme

A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

Hepatocellular carcinoma (HCC) is on the rise worldwide. HCC responds poorly to chemotherapy. Lapatinib is an inhibitor of EGFR and HER2/NEU both implicated in hepatocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in HCC